Chinese clinical-stage biopharma firm Akeso has resubmitted a draft prospectus with the Hong Kong stock exchange on Monday, exactly two months after the city board rejected its original application for an initial public offering (IPO).
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
